Actuate Therapeutics Inc (ACTU) vs Lipocine Inc. (LPCN)
A side-by-side comparison of Actuate Therapeutics Inc and Lipocine Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ACTU
Actuate Therapeutics Inc
$0.82HealthcareDelayed quote: Oct 6, 2026, 10:30 AM EDT
LPCN
Lipocine Inc.
$2.08HealthcareDelayed quote: Oct 6, 2026, 10:27 AM EDT
Total return — ACTU vs LPCN
growth of $100 · dividends reinvested · last 2yACTU -89.8% (-68.1%/yr)LPCN -52.8% (-31.3%/yr)LPCN compounded faster over this window
ACTU LPCN
ACTU vs LPCN: by the numbers
- •ACTU is the larger company ($20M vs $17M market cap).
- •Both run net losses; ACTU's is the smaller (0.00% vs -755.13% net margin).
Metrics side by side
Valuation
| Metric | ACTU | LPCN |
|---|---|---|
| P/S ratio | N/A | 10.93 |
| P/B ratio | 19.81 | 0.79 |
Profitability
| Metric | ACTU | LPCN |
|---|---|---|
| Gross margin | 0.00% | -334.26% |
| Operating margin | 0.00% | -524.69% |
| Net margin | 0.00% | -755.13% |
| ROE | -2067.81% | -54.45% |
| ROIC | -1489.99% | -57.74% |
Growth (annualized)
| Metric | ACTU | LPCN |
|---|---|---|
| Total return CAGR (5Y) | N/A | -34.76% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.